Eleven Biotherapeutics

Image of Stephen A. Hurly

Stephen A. Hurly brings nearly two decades of leadership experience in the life sciences industry. Prior to his role as president and CEO of Eleven, he joined Viventia as chief executive officer in March 2014. Previously, Mr. Hurly was the chief executive officer of Burrill & Co.'s Merchant Banking Division, a finance business for life science companies, from 2011 to 2014. Prior to that, Mr. Hurly was the head of the Life Sciences Investment Banking Practice at Boenning & Scattergood, a securities asset management and investment banking firm, from 2008 to 2011. Mr. Hurly has more than 15 years of experience in the investment banking business. Mr. Hurly currently serves on the board of directors of PHusis Therapeutics Inc., a targeted small molecule therapeutics company, since May 2011. He graduated from Swarthmore College with a B.A. degree in Engineering in 1990 and earned an M.B.A. from the University of Chicago in 1997.

Image of Gregory P. Adams, Ph.D.

Gregory P. Adams, Ph.D., serves as our chief scientific officer, leading the advancement of the company's oncology pipeline of novel Targeted Protein Therapeutics. Previously, Dr. Adams was Director of Biological Research and Therapeutics at Fox Chase Cancer Center from 2013 to 2015, where he led a laboratory group focused on developing antibodies and antibody-drug conjugates for the treatment of breast, ovarian and renal cancer. Earlier at Fox Chase Cancer Center, Dr. Adams co-lead the Center's Developmental Therapeutics Program from 2009 to 2013. Dr. Adams serves on the Editorial Boards of Cancer Immunology Research, MAbs and Cancer Biotherapy & Radiopharmaceuticals. He is a member of the Integration Panel of the U.S. Department of Defense's Breast Cancer Research Program and recently completed a four-year term as a member of the U.S. National Cancer Institute's Cancer Immunopathology and Immunotherapy Study Section. He was a co-founder of a computational antibody design company, RAbD Biotech, and has served on the Scientific Advisory Boards of a number of biotechnology companies including Endo Pharmaceuticals Inc., Symphogen A/S, Avipep Pty. Ltd., AvidBiologics (now known as Formation Biologics, Inc.) and YM Biosciences Inc. (which was acquired by Gilead Sciences, Inc.). He graduated from the University of California, Santa Cruz with a Bachelor's Degree in Biology in 1983 and earned a Ph.D. in Immunology from the University of California at Davis in 1991.

Image of Arthur DeCillis, M.D.

Arthur DeCillis, M.D., serves as our chief medical officer. Previously, Dr. DeCillis was the Vice President of Medical Affairs at Exelixis, Inc., a biotechnology company which discovered, develops and commercializes small molecules for the treatment of cancer, from 2011 to 2015. Earlier at Exelixis, Dr. DeCillis served as the company’s Vice President of Clinical Research from 2007 to 2011. Prior to that, Dr. Decillis served as a Senior Director and Executive Director at Novartis Pharmaceutical Corp. from 2005 to 2007. Previously, he held positions of increasing responsibility in Oncology Global Clinical Research at Bristol-Myers Squibb Company, culminating as group director. He graduated from Lehigh University with a Bachelor’s degree in Mathematics in 1978, received his Doctor of Medicine degree from the University of Rochester School of Medicine and Dentistry in 1984 and received a M.S. degree in Intelligent Systems from the University of Pittsburgh in 1994. He completed his internship and residency in Internal Medicine at the Medical College of Virginia and a Fellowship in Medical Informatics at the University of Pittsburgh. He is Board Certified in Internal Medicine.

Image of Glen MacDonald, PhD

Glen C. MacDonald, Ph.D., serves as our chief technology officer. Previously, Dr. MacDonald served our predecessor company in several research related capacities from 1997 to 2005. Prior to joining us, Dr. MacDonald held a Manitoba Cancer Treatment Research Foundation Fellowship from 1996 to 1997 while serving as a Post-Doctoral Fellow at the University of Manitoba Cancer Treatment Research Foundation from 1995 to 1997. Dr. MacDonald also served as a Canadian Arthritis Society Post-Doctoral Fellow at the University of North Carolina at Chapel Hill from 1993 to 1995. He graduated from the University of Guelph with a Bachelor’s Degree in Genetics in 1980 and earned an M.Sc. and Ph.D. from the University of Manitoba in 1987 and 1993, respectively. Dr. MacDonald’s scientific background is extensive, having published in the areas of monoclonal antibodies, graft versus-host disease, lupus and apoptosis.

Image of John McCabe, C.P.A.

John McCabe brings more than 20 years of finance and accounting experience to Eleven. Prior to joining Eleven, he was Vice President of Finance at Clinical Data, Inc., a drug developer that was acquired by Forest Laboratories after FDA approval of its lead drug product for depression, Viibryd®. Prior to that, Mr. McCabe served in several financial roles at Interleukin Genetics, Inc., a genetics-focused personalized health company; and SatCon Technology Corporation, a developer of innovative power conversion solutions. John began his career working for the accounting firm of Coopers & Lybrand LLP, now known as PricewaterhouseCoopers LLP. He received a B.S. in Business Administration from the University of Vermont and is also a Certified Public Accountant.

- 0.02
Day High:
Day Low:
4:00 PM ET on September 22, 2017
Delayed at least 20 minutes.